Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up (Q46483469)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2005

Language	Label	Description	Also known as
English	Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up	scientific article published in January 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

1 reference

based on heuristic

inferred from title

Alessandra Mosca

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Francesco Porpiglia

10

object named as

Francesco Porpiglia

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Luigi Dogliotti

14

object named as

Luigi Dogliotti

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Alfredo Berruti

1

object named as

Alfredo Berruti

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

3

object named as

Marcello Tucci

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

author name string

Enrica Fara

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Roberto Tarabuzzi

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Carlo Terrone

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Gabriella Gorzegno

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Giuseppe Fasolis

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Marco Tampellini

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Marinella De Stefanis

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Dario Fontana

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Gruppo Onco-Urologico Piemontese, Rete Oncologica Piemontese

15

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

23

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

1-7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

State-of-the-art treatment of metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Novel endpoints and design of early clinical trials

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Circulating neuroendocrine markers in patients with prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Neuroendocrine differentiation in prostatic malignancy

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Chemotherapy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2004.06.003

7 January 2021

Identifiers

10.1016/J.UROLONC.2004.06.003

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

release_tpsfwlpbtvfobikg4kka4uqaeq

1 reference

https://api.fatcat.wiki/v0/release/tpsfwlpbtvfobikg4kka4uqaeq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15885575

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46483469&oldid=2113435843"